About Endosomal transmembrane epsin interactor 1
Endosomal transmembrane epsin interactor 1 (ENTREP1) is a protein
from Homo sapiens identified by UniProt accession
Q15884, 450 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | Endosomal transmembrane epsin interactor 1 |
| UniProt accession | Q15884 |
| Gene | ENTREP1 |
| Organism | Homo sapiens |
| Length | 450 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (48)
Diseases linked to this target (Open Targets).
- glucose measurement · score 0.24
- intelligence · score 0.12
- self reported educational attainment · score 0.12
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- schizophrenia · score 0.09
- red blood cell density measurement · score 0.08
- hemoglobin measurement · score 0.07
- breast cancer · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15884-F1 | alphafold | PREDICTED | 60.58 | — |
Amino-acid sequence (450 residues)
MILLVNLFVL LSVVCVLLNL AGFILGCQGA QFVSSVPRCD LVDLGEGKIC FCCEEFQPAK CTDKENALKL FPVQPCSAVH LLLKKVLFAL CALNALTTTV CLVAAALRYL QIFATRRSCI DESQISAEEA EDHGRIPDPD DFVPPVPPPS YFATFYSCTP RMNRRMVGPD VIPLPHIYGA RIKGVEVFCP LDPPPPYEAV VSQMDQEQGS SFQMSEGSEA AVIPLDLGCT QVTQDGDIPN IPAEENASTS TPSSTLVRPI RSRRALPPLR TRSKSDPVLH PSEERAAPVL SCEAATQTER RLDLAAVTLR RGLRSRASRC RPRSLIDYKS YMDTKLLVAR FLEQSSCTMT PDIHELVENI KSVLKSDEEH MEEAITSASF LEQIMAPLQP STSRAHKLPS RRQPGLLHLQ SCGDLHTFTP AGRPRAERRP RRVEAERPHS LIGVIRETVL
Explore Endosomal transmembrane epsin interactor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets